Difference between revisions of "Bavituximab (PGN-401)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
m |
||
| Line 15: | Line 15: | ||
[[Category:Anti-PS antibodies]] | [[Category:Anti-PS antibodies]] | ||
| − | [[Category:Non-small cell lung cancer medications]] | + | [[Category:Non-small cell lung cancer medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 02:18, 29 April 2022
Mechanism of action
Binds to phosphatidylserine, provoking an immune response.
Preliminary data
Non-small cell lung cancer
- Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. link to original article PubMed
Also known as
- Code name: PGN401
- Brand name: Tarvacin